Ask AI
Back Back
ProCE Banner Activity

Closing Practice Gaps in Systemic Mastocytosis: A Skills-Based Intensive for APPs

Slideset

Early recognition and effective management of systemic mastocytosis (SM) require advanced practice providers to think beyond the skin, as systemic symptoms often present alongside cutaneous involvement. Learn how to better recognize, diagnose, and manage SM in your practice by understanding its heterogeneous clinical presentations, the evolving evidence, and the importance of multidisciplinary care coordination.

Released: July 29, 2026

Begin Activity

Share

Faculty

Carole Bitar

Carole Bitar, MD, FAAD

Associate Professor
Department of Dermatology and Dermatopathology
Tulane University School of Medicine
New Orleans, Louisiana
Matthew P. Giannetti

Matthew P. Giannetti, MD

Associate Director of Brigham and Women’s Hospital Mastocytosis Center
Assistant Professor of Medicine, Harvard Medical School
Brigham and Women’s Hospital, Division of Allergy and Clinical Immunology
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Blueprint Medicines Corporation.

Blueprint Medicines Corporation

Target Audience

This educational program is intended for dermatology nurse practitioners and physician associates, other advanced practice providers, such as those practicing in primary care, who are engaged in the care of patients with SM.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the underlying biology and disease heterogeneity of systemic mastocytosis, including key pathogenic mechanisms, clinical phenotypes, and conditions that commonly mimic SM in practice

  • Apply current consensus diagnostic frameworks—including clinical, laboratory, and pathologic criteria—to accurately identify systemic mastocytosis and determine disease subtype

  • Critically appraise emerging clinical evidence on targeted and disease-modifying therapies for systemic mastocytosis to support appropriate treatment selection and sequencing

  • Develop individualized, patient-centered management strategies that integrate shared decision-making, symptom burden, comorbidities, and multidisciplinary care coordination for patients with SM

Financial Disclosures

Primary Author

Carole Bitar, MD, FAAD: consultant/advisor/speaker/researcher: Arcutis.

Matthew P. Giannetti, MD: consultant/advisor/speaker: Blueprint, Cogen Biosciences, InmageneBio, NemaGen, Novartis, Palindrome.